Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
34 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bluebird bio, Inc. - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'Bluebird bio, Inc. - Product Pipeline Review - 2015', provides an overview of the Bluebird bio, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Bluebird bio, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Bluebird bio, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Bluebird bio, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Bluebird bio, Inc.'s pipeline products Reasons to buy - Evaluate Bluebird bio, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Bluebird bio, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Bluebird bio, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Bluebird bio, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bluebird bio, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of Bluebird bio, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Bluebird bio, Inc. Snapshot 5 Bluebird bio, Inc. Overview 5 Key Information 5 Key Facts 5 Bluebird bio, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Bluebird bio, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Bluebird bio, Inc. - Pipeline Products Glance 12 Bluebird bio, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Bluebird bio, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Bluebird bio, Inc. - Drug Profiles 15 BB-305 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Lenti-D 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 bb-2121 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Cellular Immunotherapy for Hematological Malignancy and Solid Tumors 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Cellular Immunotherapy to Target BCMA for Multiple Myeloma 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Gene Therapy for Undisclosed Indication 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Bluebird bio, Inc. - Pipeline Analysis 23 Bluebird bio, Inc. - Pipeline Products by Target 23 Bluebird bio, Inc. - Pipeline Products by Route of Administration 24 Bluebird bio, Inc. - Pipeline Products by Molecule Type 25 Bluebird bio, Inc. - Pipeline Products by Mechanism of Action 26 Bluebird bio, Inc. - Recent Pipeline Updates 27 Bluebird bio, Inc. - Dormant Projects 31 Bluebird bio, Inc. - Locations And Subsidiaries 32 Head Office 32 Other Locations & Subsidiaries 32 Appendix 33 Methodology 33 Coverage 33 Secondary Research 33 Primary Research 33 Expert Panel Validation 33 Contact Us 33 Disclaimer 34
List of Tables
Bluebird bio, Inc., Key Information 5 Bluebird bio, Inc., Key Facts 5 Bluebird bio, Inc. - Pipeline by Indication, 2015 7 Bluebird bio, Inc. - Pipeline by Stage of Development, 2015 8 Bluebird bio, Inc. - Monotherapy Products in Pipeline, 2015 9 Bluebird bio, Inc. - Partnered Products in Pipeline, 2015 10 Bluebird bio, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 11 Bluebird bio, Inc. - Phase II, 2015 12 Bluebird bio, Inc. - Phase I, 2015 13 Bluebird bio, Inc. - Preclinical, 2015 14 Bluebird bio, Inc. - Pipeline by Target, 2015 23 Bluebird bio, Inc. - Pipeline by Route of Administration, 2015 24 Bluebird bio, Inc. - Pipeline by Molecule Type, 2015 25 Bluebird bio, Inc. - Pipeline Products by Mechanism of Action, 2015 26 Bluebird bio, Inc. - Recent Pipeline Updates, 2015 27 Bluebird bio, Inc. - Dormant Developmental Projects,2015 31 Bluebird bio, Inc., Other Locations 32 Bluebird bio, Inc., Subsidiaries 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.